Digital Biomarkers Market

Digital Biomarkers Market - Distribution by Type of Product (Software / Applications, Wearables, and Others), Purpose of Solution (Diagnosis, Early Detection, Monitoring, and Predictive Insights), Type of Biomarker (Cognitive, Idiosyncratic, Physiological, Vocal, and Others), Therapeutic Area (Autoimmune Disorders, Cardiovascular Disorders, Infectious Disorders, Mental Health Disorders, Neurological Disorders, Respiratory Disorders, Substance Abuse Disorders and Others), Business Model (B2B and B2C) and Key Geographical Regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts

The digital biomarkers market is valued at USD 5.55 billion in 2024 growing at a CAGR of 18.5% during the forecast period 2024-2035.

The conventional approach of manually tracking individuals' health data is fraught with numerous challenges, including delays in assessing critical health information, susceptibility to errors, time-consuming and costly processes, and the risk of loss or damage to health records. These factors hinder timely treatment, particularly for the aging population. Alarmingly, it is estimated that 65% of hospital patients and more than 90% of post-acute care patients undergo manual monitoring of vitals and patient-specific parameters every four to eight hours. As a result, telemedicine has gained prominence, leveraging digital tools to provide remote consultations and services. Notably, digital health technologies enable continuous patient monitoring, allowing healthcare practitioners to promptly track baseline changes in individual patients. Additionally, the implementation of continuous monitoring systems has proven to significantly reduce adverse events and hospital readmissions. The burgeoning fields of digital biomarkers and digital therapeutics are integral components of the broader digital health market. Furthermore, according to the World Health Organization, by 2030, one-sixth of the global population will be aged over 60 years. Consequently, proactively detecting symptoms at an early stage is intuitively better than treating patients who are seriously ill due to longer waiting times. Studies have demonstrated that continuous symptom tracking with early intervention has not only led to remarkable improvements in patients' quality of life but has also reduced healthcare costs.

The rising digitalization in the healthcare industry has catalyzed the development of several digital solutions capable of generating, collecting, and tracking medical information via biomarkers in the body. Digital solutions for biomarkers are defined as digital devices, such as smartphones, sensors, and wearable devices, that measure and quantify physiological, behavioral, or biometric data, including blood pressure, emotional health, heart rate, glucose levels, physical activity, respiratory function, and sleep patterns. These advanced solutions enable real-time monitoring of an individual's health, specifically in chronic disease management, encourage proactive participation in wellness activities, and allow personalized healthcare by tailoring treatments based on individual data. With the rising prevalence of chronic diseases, growing emphasis on remote patient monitoring, and continuous advancements in technologies, the digital biomarkers market is poised for growth in the foreseeable future.

Key Market Segments

Type of Product

Software / Applications

Wearables

Sensors

Gaming Solutions

Purpose of Solution

Diagnosis

Early Detection

Monitoring

Predictive Insights

Type of Biomarker

Cognitive Biomarkers

Idiosyncratic Biomarkers

Physiological Biomarkers

Vocal Biomarkers

Other Biomarkers

Therapeutic Area

Autoimmune Disorders

Cardiovascular Disorders

Infectious Diseases

Mental Health Disorders

Neurological Disorders

Respiratory Disorders

Substance Abuse Disorders

Others

Business Model

B2B

B2C

Geographical Regions

North America

Europe

Asia-Pacific

Middle East and North Africa (MENA)

Rest of the World

Research Coverage:

The report studies the digital biomarkers market based on type of product, purpose of solution, type of biomarker, therapeutic area, business model, and key geographical regions

The report assesses the potential advantages and obstacles within the market for those involved and offers information on the competitive environment for top players in the market.

The report forecasts the revenue of market segments with respect to five major regions

The report begins with a general overview of various solutions enabling digital monitoring / detection of biomarkers. It provides information on different types of digital biomarkers, biological signals captured by them, key advantages driving their growing adoption, existing concerns around reliability/credibility of analyzed health data and lack of guidelines. It also outlines the product development and commercialization path for digital biomarkers and highlights recent advances and prevalent trends in this field.

It offers a detailed assessment of the current digital biomarker solutions market landscape based on parameters like product type (software/apps, wearables, others), solution type (data collection, data integration), biomarker type (behavioral, cognitive, idiosyncratic, physiological, vocal, others), development status (approved, FDA registered, marketed, R&D), purpose (diagnosis, disease risk management, early detection, monitoring, prognosis, treatment), therapeutic area, target population, end-user type, clinical validation status, and AI integration. It also analyzes digital biomarker developers by year of establishment, company size, headquarters location, business model, and active players.

The report provides an insightful analysis of digital biomarker solutions based on developer strength (experience, size, model, number of solutions), product competitiveness (solution type, biomarker type, purpose, clinical validation, AI integration), and development status.

It includes elaborate profiles of key digital biomarker developers, featuring company overviews, biomarker portfolios, recent developments, and future outlooks.

The report presents a detailed analysis of partnerships between stakeholders from pre-2019 to 2024, based on year, partnership type, biomarker type, therapeutic area, partner type, active players, and regional distribution.

It features an analysis of funding/investments raised by digital biomarker developers based on year, funding type, amount, biomarker type, therapeutic area, active players/investors, and regional distribution.

The report analyzes global events attended by companies in this industry, based on year, event type, platform, organizer, location, active players, speakers, and designations.

It provides an in-depth analysis of digital biomarker patents filed/granted since 2019, based on patent type, publication/application year, jurisdiction, CPC symbols, applicant type, active players, benchmarking, and a patent valuation analysis highlighting leading patents by citations.

The report analyzes initiatives by big pharma players related to digital biomarkers, based on parameters like number of clinical trials, collaborations, conferences attended, funding instances, and publications.

It identifies and analyzes key drivers, restraints, opportunities, and challenges impacting the growth of the digital biomarkers market.

The report provides a detailed market forecast analysis to estimate the existing market size and future opportunity till 2035, based on likely adoption trends and primary validations. It includes three forecast scenarios (conservative, base, optimistic) to account for future uncertainties.

It offers detailed projections of the current and future market opportunity across product types (software / apps, wearables, sensors, gaming solutions), solution purposes (diagnosis, early detection, monitoring, predictive insights), biomarker types (cognitive, idiosyncratic, physiological, vocal, others), therapeutic areas, business models (B2B, B2C), and key geographical regions.

Key Benefits of Buying this Report

The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.

Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.

The report provides stakeholders with a pulse on the digital biomarkers market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Key Market Companies

Acculi Labs

ActiGraph

AliveCor

ATCOR

BACtrack

Biogen

BioSerenity

BioSensics

Eyenuk

Empatica

Feel Therapeutics

icometrix

iMediSync

IXICO

Kinsa

Koneksa Health

Kontigo Care

Progentec Diagnostics

Quibim

Vocalis Health